Francis Cuss Net Worth

The estimated Net Worth of Francis M Cuss is at least $8.09 Million dollars as of 20 July 2018. Francis Cuss owns over 10,000 units of Rubius Therapeutics Inc stock worth over $830 and over the last 14 years he sold RUBY stock worth over $7,775,501. In addition, he makes $314,285 as Independent Director at Rubius Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Francis Cuss RUBY stock SEC Form 4 insiders trading

Francis has made over 27 trades of the Rubius Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of RUBY stock worth $230,000 on 20 July 2018.

The largest trade he's ever made was exercising 147,618 units of Rubius Therapeutics Inc stock on 30 August 2012 worth over $3,009,931. On average, Francis trades about 22,296 units every 75 days since 2011. As of 20 July 2018 he still owns at least 10,000 units of Rubius Therapeutics Inc stock.

You can see the complete history of Francis Cuss stock trades at the bottom of the page.

Francis Cuss biography

Dr. Francis M. Cuss serves as Independent Director of the Company. Dr. Cuss is currently retired from full-time operational roles. Previously, he served as the Executive Vice President, Chief Scientific Officer and Head of Research and Development of Bristol Myers Squibb Co., a pharmaceutical company, from July 2013 to March 2017, and as the Senior Vice President and Head of Research of Bristol Myers Squibb from April 2010 to June 2013. Since September 2017, Dr. Cuss has served on the board of directors of Novo Holdings A/S and since July 2019, Dr. Cuss has served on the board of directors of Glympse Bio, Inc. Dr. Cuss also currently serves on the Advisory Committee of the Director of the National Institutes of Health. Dr. Cuss received a B.A./M.A. in natural sciences and an M.B., B.Chir. in medicine from Cambridge University. Cuss' broad experience in pharmaceutical research, clinical development and executive management within globally-operating biopharmaceutical companies make him qualified to serve on our board of directors.

What is the salary of Francis Cuss?

As the Independent Director of Rubius Therapeutics Inc, the total compensation of Francis Cuss at Rubius Therapeutics Inc is $314,285. There are 10 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.

How old is Francis Cuss?

Francis Cuss is 65, he's been the Independent Director of Rubius Therapeutics Inc since 2018. There are 2 older and 16 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Francis Cuss's mailing address?

Francis's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE, MA, 02139.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Francis Cuss stock trades at Bristol-Myers Squibb Co and Rubius Therapeutics Inc

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President